{"id":2353,"date":"2024-03-18T13:54:14","date_gmt":"2024-03-18T13:54:14","guid":{"rendered":"https:\/\/sites.exeter.ac.uk\/psychedelics\/?page_id=2353"},"modified":"2024-03-18T13:54:14","modified_gmt":"2024-03-18T13:54:14","slug":"michelle-baker-jones","status":"publish","type":"page","link":"https:\/\/sites.exeter.ac.uk\/psychedelic-colloquium-archive\/michelle-baker-jones\/","title":{"rendered":"Michelle Baker Jones<\/strong>"},"content":{"rendered":"\n

Contributor – Speaker<\/h2>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Michelle is an integrative psychotherapeutic counsellor based in London, where she has a private practice. She has been a member of Imperial College’s Psychedelic Research Group since 2015. Michelle was a lead guide on Imperial College\u2019s randomised controlled trial (Psilodep 2) comparing psilocybin to escitalopram in the treatment of depression. <\/p>\n\n\n\n

She has recently been working as a lead therapist for Small Pharma\u2019s clinical trials with DMT-assisted therapy for depression. This was originally a collaboration between Small Pharma and Imperial College London. She co-designed the Beckley Academy Foundations to Psychedelic-Assisted Therapy training course. Michelle has contributed to the development of a therapist training00programme for the DMT trials, having co-produced a psychedelic therapy framework for working with DMT.  <\/p>\n\n\n\n

Michelle offers individual psychedelic integration for people who are struggling to process psychedelic experiences. She co-facilitates the psychedelic integration specialist interest group for The Institute of Psychedelic Therapy, drawing on her experience of facilitating integration groups over the past five years.<\/p>\n\n\n\n

www.mbjcounselling.co.uk<\/a><\/p>\n\n\n\n

https:\/\/www.imperial.ac.uk\/psychedelic-research-centre\/about-the-centre-and-cippres\/people\/<\/a><\/p>\n\n\n\n

\n\n\n\n

Colloquium Presentation: 22 March 2024, 3.30-5pm (speaking in person)<\/p>\n\n\n\n

\n\n\n\n

Title: DMT- Assisted psychotherapy for Depression ( TRACE – DMT Framework )<\/strong> <\/p>\n\n\n\n

Graham and Michelle will share their experience of working with DMT-assisted psychotherapy as a potential treatment for depression. They will describe the Phase I and IIa trials and share some of the experiences of healthy volunteers and patients in the trials. They hope to provide an insight into the participant journey through the trials and the broad nature of their psychedelic experiences. They will present the main findings from both trials whilst offering reflection on their experience of working with DMT as a potential therapeutic tool.<\/p>\n\n\n\n

<\/h1>\n\n\n\n
\n